CKM Syndrome Screening and Tests: How Risk Is Assessed

Cardiovascular-kidney-metabolic (CKM) syndrome is not identified with one blood test, scan, or symptom checklist. Screening involves looking at several parts of health together: body composition, blood pressure, glucose regulation, blood lipids, kidney function, urine albumin, cardiovascular history, and, for appropriate adults, estimated cardiovascular risk.

The 2026 AHA/ACC/ADA/ASN CKM syndrome guideline recommends staging people by assessing metabolic risk factors, kidney function, and cardiovascular disease status together. The goal is to recognize risk before serious cardiovascular or kidney complications develop and to adjust the intensity of monitoring and prevention as risk increases.

For many people, the most important CKM screening tools are ordinary measurements already used in primary care. More specialized testing, such as coronary artery calcium imaging or cardiac biomarkers, is reserved for situations in which it could meaningfully clarify cardiovascular risk or change clinical decisions.

Is There a Test for CKM Syndrome?

There is no single laboratory result that comes back as “positive” or “negative” for CKM syndrome.

Instead, clinicians build a CKM assessment from several types of information. The 2026 guideline recommends examining metabolic risk factors, kidney function, and cardiovascular status together because abnormalities in these systems can interact and affect a person’s overall risk.

For an adult, the evaluation may include body mass index (BMI), waist circumference, blood pressure, blood glucose or HbA1c, cholesterol and triglycerides, estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), medical history, and cardiovascular risk estimation.

Not everyone needs every possible test. A healthy adult in CKM Stage 0, for example, generally needs less frequent laboratory monitoring than someone with diabetes, hypertension, chronic kidney disease, or established cardiovascular disease.

That risk-based approach is one of the defining features of CKM care.

Body Weight and Waist Circumference

Assessing adiposity is an early part of CKM screening because excess and dysfunctional adipose tissue can contribute to insulin resistance, high blood pressure, abnormal lipids, type 2 diabetes, inflammation, and cardiovascular risk.

The 2026 guideline recommends measuring BMI and waist circumference at least annually in adults who have or are at risk for CKM syndrome. Waist circumference is useful in addition to BMI because it provides information about abdominal adiposity, which BMI alone cannot show.

Neither measurement is perfect.

BMI cannot distinguish fat mass from muscle mass or show where fat is distributed. Waist circumference also requires consistent measurement technique and may not fully reflect metabolic health in every individual.

For that reason, CKM assessment does not use body size in isolation. Someone’s glucose, blood pressure, lipids, kidney measurements, and cardiovascular risk still matter.

Blood Pressure

Blood pressure is a particularly important CKM measurement because hypertension can affect the heart, arteries, kidneys, and brain while causing no noticeable symptoms.

The 2026 CKM guideline recommends blood-pressure assessment at least annually across adult CKM stages, with more frequent measurement often appropriate when hypertension is present or treatment is being adjusted.

One office reading does not always represent a person’s usual blood pressure. Measurements may be influenced by recent exercise, caffeine, stress, pain, incorrect cuff size, or measurement technique.

When appropriate, clinicians may use repeated office readings, home blood-pressure monitoring, or ambulatory monitoring to obtain a clearer picture.

Blood pressure is therefore both a screening measurement and, when elevated, something that generally needs confirmation and ongoing monitoring rather than interpretation from a single isolated value.

Blood Glucose and HbA1c

Glucose testing helps identify impaired glucose regulation, prediabetes, and diabetes, all of which are relevant to CKM staging.

Two commonly used measurements are fasting plasma glucose and hemoglobin A1c, or HbA1c.

Fasting glucose provides a snapshot of blood glucose after a period without food. HbA1c estimates average glucose exposure over approximately the previous two to three months by measuring the percentage of hemoglobin with glucose attached.

An oral glucose tolerance test may also be used in selected circumstances.

These measurements can identify metabolic abnormalities before a person develops classic symptoms of diabetes. That is particularly important in CKM syndrome because Stage 1 can include prediabetes, while type 2 diabetes is among the conditions that can place someone in Stage 2.

The appropriate interpretation of glucose results depends on clinical context, and abnormal results may need confirmation unless the clinical picture clearly establishes diabetes.

Cholesterol and Triglycerides

A lipid panel helps clinicians evaluate cardiovascular and metabolic risk.

Common measurements include total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. These values contribute to decisions about cardiovascular prevention, and some are also used directly in cardiovascular risk equations.

Triglycerides are particularly relevant to CKM staging because elevated triglycerides are one of the metabolic abnormalities included within Stage 2.

LDL cholesterol does not by itself determine someone’s CKM stage in the same way, but it remains highly important when assessing atherosclerotic cardiovascular risk and deciding how aggressively that risk should be managed.

The CKM approach therefore does not replace conventional lipid assessment. It places those results within the broader context of metabolic health, kidney function, and cardiovascular risk.

Kidney Testing: Why Both eGFR and UACR Matter

Kidney assessment is one of the most important—and sometimes overlooked—parts of CKM screening.

Two measurements provide complementary information:

eGFR estimates how effectively the kidneys are filtering blood.

UACR measures the amount of albumin in the urine relative to urine creatinine and can reveal kidney damage even when filtration remains relatively well preserved.

The 2026 CKM guideline recommends eGFR assessment in people with or at risk for CKM syndrome and recommends adding UACR in adults at CKM Stage 2 or above. At those stages, both tests should generally be assessed at least annually.

What eGFR Measures

Estimated glomerular filtration rate is usually calculated from a blood creatinine measurement along with other information using a validated equation.

A lower eGFR generally indicates reduced kidney filtration. However, eGFR is an estimate rather than a direct measurement, and creatinine can be influenced by factors such as muscle mass.

KDIGO recommends using validated GFR-estimating equations rather than interpreting serum creatinine alone. In situations where creatinine-based eGFR may be less accurate, combining creatinine with another filtration marker called cystatin C can improve estimation when the test is available and clinically useful.

A single reduced eGFR does not automatically establish chronic kidney disease. CKD involves abnormalities of kidney structure or function that persist for at least three months, so repeat testing and clinical context can be important.

What UACR Measures

Healthy kidneys normally prevent most albumin, a blood protein, from leaking into the urine.

When the kidney’s filtering structures are damaged, albumin can begin appearing in the urine. UACR helps quantify that leakage.

KDIGO categorizes albuminuria broadly as:

UACR	Albuminuria category	General interpretation
Below 30 mg/g	A1	Normal to mildly increased
30–299 mg/g	A2	Moderately increased
300 mg/g or higher	A3	Severely increased

These categories are clinically important because higher albuminuria is associated with greater risks of CKD progression and cardiovascular disease. Kidney risk is assessed using both albuminuria and eGFR, rather than either measurement alone.

Why a Normal eGFR Does Not Always Rule Out Kidney Disease

A person can have meaningful albuminuria while their eGFR is still relatively preserved.

Conversely, someone can have reduced eGFR without a large amount of albumin in the urine.

That is why the two measurements complement each other. Using eGFR alone can miss some forms of kidney damage, while UACR alone does not show how effectively the kidneys are filtering blood.

The CKM framework gives kidney assessment particular importance because CKD substantially affects cardiovascular risk and can influence both staging and treatment decisions.

Why an Abnormal UACR May Need to Be Repeated

Albumin excretion can fluctuate.

Recent vigorous exercise, fever, infection, marked hyperglycemia, menstruation, heart failure, and severely elevated blood pressure can temporarily increase urine albumin. The 2026 ADA Standards of Care also note substantial biological variability in UACR and recommend confirmation when persistent albuminuria is being established.

KDIGO similarly advises confirming an abnormal random UACR result with an appropriate follow-up sample, preferably a first-morning specimen when practical.

An isolated abnormal result therefore should not be interpreted without context.

How the PREVENT Calculator Fits Into CKM Screening

Laboratory tests tell clinicians what is happening now. Cardiovascular risk equations help estimate what may happen over time.

The PREVENT equations, developed by the American Heart Association, were designed specifically to incorporate cardiovascular, kidney, and metabolic information into modern risk prediction.

PREVENT stands for Predicting Risk of Cardiovascular Disease EVENTS.

For adults without established cardiovascular disease, the equations can estimate the future risk of:

• Atherosclerotic cardiovascular disease, including heart attack and stroke
• Heart failure
• Total cardiovascular disease, combining ASCVD and heart failure

The 2026 CKM guideline recommends using PREVENT to estimate 10-year cardiovascular risk in appropriate asymptomatic adults ages 30 to 79. For adults ages 30 to 59, 30-year risk can also be useful, particularly when short-term risk looks low because of younger age but long-term risk may still be substantial.

What Information PREVENT Uses

The base PREVENT models incorporate commonly available information such as age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, smoking status, kidney function measured through eGFR, and use of certain cardiovascular medications. BMI is also incorporated for heart-failure prediction.

Optional versions can incorporate HbA1c, UACR, and measures of social deprivation when that information is available.

Race is not used as an input in the PREVENT equations.

Why PREVENT Matters for CKM Staging

PREVENT is not merely an optional calculator added to the CKM framework. Risk estimates can actually affect staging.

Under the 2026 guideline, a 10-year predicted total cardiovascular disease risk of 20% or greater using PREVENT-CVD is one pathway by which an adult can meet Stage 3 CKM criteria, even without known clinical cardiovascular disease.

Risk estimates can also help clinicians decide how strongly to prioritize preventive interventions.

However, PREVENT does not predict an individual’s future with certainty. Risk equations estimate probabilities based on populations, and the CKM guideline notes that inaccuracies remain possible, especially when important risk factors are not captured or particular populations are underrepresented.

The result should therefore support clinical judgment and shared decision-making rather than replace them.

Do You Need a Coronary Artery Calcium Scan?

Not everyone being evaluated for CKM syndrome needs cardiac imaging.

A coronary artery calcium (CAC) scan is a specialized CT scan that detects calcium within coronary artery plaque. A higher CAC score generally indicates a greater burden of coronary atherosclerosis.

The 2026 CKM guideline states that CAC testing can be useful for certain adults whose estimated ASCVD risk falls into an intermediate range—and selected adults at borderline risk—when the decision about preventive therapy remains uncertain.

The important phrase is when it would change a decision.

CAC scanning is not intended as a routine test for every person with obesity, prediabetes, hypertension, or another CKM risk factor. Clinicians weigh age, estimated risk, existing medical conditions, previous testing, radiation exposure, and whether the result would meaningfully alter management.

In CKM staging, substantial subclinical coronary atherosclerosis can also contribute to Stage 3 classification.

When Cardiac Biomarkers or Heart Imaging May Be Considered

The CKM framework also recognizes that heart failure can begin with structural or biological changes before a person develops classic symptoms.

For adults with an elevated predicted risk of heart failure—specifically a PREVENT-HF 10-year risk of at least 5%—the 2026 guideline says assessment with certain cardiac biomarkers can be beneficial when it would help guide further testing or prevention. These biomarkers include natriuretic peptides such as BNP or NT-proBNP and high-sensitivity cardiac troponin.

Abnormal findings may lead to additional evaluation such as cardiac imaging, depending on the clinical situation.

Again, these are selective tests, not part of a universal CKM laboratory panel.

A healthy person should not assume that CKM screening requires an echocardiogram, CT scan, troponin test, or other advanced cardiovascular testing. The value of those tests depends on baseline risk and whether the result is likely to influence care.

How Often Should CKM Screening Be Repeated?

One of the useful features of the 2026 guideline is that it provides different monitoring intervals according to CKM stage rather than using one schedule for everyone.

Current CKM status	Suggested minimum adult monitoring under the 2026 guideline
All adults with or at risk for CKM	BMI and waist circumference at least annually
Stage 0	Blood pressure at least annually; lipids, glycemia, and eGFR at least every 5 years
Stage 1	Blood pressure at least annually; lipids, glycemia, and eGFR at least every 2–3 years
Stage 2 or higher	Blood pressure, lipids, and glycemia at least annually
Stage 2 or higher	Both eGFR and UACR at least annually

These are minimum guideline intervals, not individualized appointment schedules.

People with advanced CKD, poorly controlled risk factors, medication changes, rapidly changing laboratory results, or other clinical concerns may require substantially more frequent monitoring. The guideline notes that eGFR and UACR can be assessed every three to six months in some people with more advanced CKD, consistent with kidney-disease guidance.

KDIGO likewise recommends assessing GFR and albuminuria at least annually in people with CKD and more often when the risk of progression is higher and the result would influence treatment decisions.

How Screening Changes for People With Diabetes

People with diabetes receive particular attention because diabetes is a major cause of chronic kidney disease and substantially affects cardiovascular risk.

The American Diabetes Association’s 2026 Standards of Care recommend assessing kidney function with both eGFR and UACR at least annually in everyone with type 2 diabetes, regardless of treatment. Annual testing is also recommended in people with type 1 diabetes once its duration reaches at least five years.

Once CKD is present, testing may occur between one and four times per year depending on kidney-disease severity and risk.

This overlaps closely with the CKM approach because kidney disease can substantially change both cardiovascular risk and treatment priorities in people with diabetes.

Can Home Tests Tell You Your CKM Stage?

Home monitoring can provide useful pieces of information, but it generally cannot establish CKM stage by itself.

A properly used home blood-pressure monitor can help identify patterns that might not be obvious from occasional clinic readings. People with diabetes may also monitor glucose at home when appropriate for their treatment.

But CKM staging may require laboratory measurements such as HbA1c, lipid levels, eGFR, and UACR, as well as medical history and cardiovascular risk estimation. In higher-risk situations, it may also depend on imaging, biomarkers, or documented cardiovascular disease.

Consumer wearables can provide additional information about physical activity, heart rate, or rhythm notifications, but they are not substitutes for a complete CKM assessment.

A smartwatch alert, home glucose value, or single blood-pressure reading should therefore be viewed as one piece of health information—not as a CKM diagnosis.

What Happens if a Screening Result Is Abnormal?

An abnormal result does not always mean a person has a chronic disease.

Clinicians first consider whether the finding is likely to be persistent and whether temporary factors may have affected it. Depending on the measurement, this may mean repeating blood pressure, glucose, kidney, or urine testing.

They also look at results collectively.

For example, elevated UACR may carry different implications when combined with reduced eGFR, diabetes, and hypertension than when it occurs once during an acute illness. Similarly, an elevated blood-pressure reading means more when it forms part of a consistent pattern.

If abnormalities are confirmed, the next step is generally to determine the relevant CKM stage, estimate cardiovascular and kidney risk, and address the underlying risk factors or diseases.

That does not automatically mean medication. Depending on the person’s situation, care may involve nutrition, physical activity, weight management, smoking or nicotine cessation, sleep, blood-pressure management, lipid treatment, diabetes care, kidney-protective therapies, or combinations of these approaches.

Our guide to lifestyle changes that support CKM health explains the nonpharmacologic side of prevention in more detail.

CKM Screening Is About Connecting the Results

The defining feature of CKM screening is not any individual test. It is the decision to interpret metabolic, kidney, and cardiovascular findings together.

A blood-pressure reading provides one part of the picture. HbA1c and lipids add information about metabolic health. eGFR and UACR reveal different aspects of kidney status. PREVENT estimates help translate several of those findings into cardiovascular risk. Specialized imaging or biomarkers may provide further information for selected people.

This integrated assessment can reveal clinically important risk even when someone feels healthy.

It also avoids the opposite problem: assuming that every abnormal number has the same significance for every person. Age, stage, medical history, existing disease, medications, and overall risk all influence how a result should be interpreted.

For readers, the practical message is that CKM syndrome should not be self-diagnosed from one laboratory value. The most useful assessment is a coordinated review of metabolic, kidney, and cardiovascular health, followed by testing at intervals appropriate for the person’s actual risk.

This article provides general educational information and is not a substitute for individualized medical evaluation. Screening intervals, diagnostic testing, and interpretation of abnormal results should be tailored by a qualified healthcare professional.

References

1. Ndumele CE, Rodriguez F, Dixon DL, et al. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.” Circulation and Journal of the American College of Cardiology, 2026.
2. American Heart Association. “Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) Calculator.” Professional Heart Daily, current clinical resource.
3. Kidney Disease: Improving Global Outcomes CKD Work Group. “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.” Kidney International, 2024;105(4S):S117–S314.
4. American Diabetes Association Professional Practice Committee for Diabetes. “11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026.” Diabetes Care, 2026;49(Suppl 1):S246 onward.